Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheap chemical could supercharge breast cancer radiation

NCT ID NCT03946202

Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 4 times

Summary

This study tests whether injecting a very dilute hydrogen peroxide solution directly into breast tumors can make standard radiotherapy more effective. Researchers are enrolling 184 adults with locally advanced or recurrent breast cancer. Participants will receive injections twice a week during their radiotherapy course. Early results from Japan suggest this approach may dramatically improve tumor shrinkage, but the treatment is still experimental and limited to certain patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hydrogen peroxide
What this could lead to
If it works, this cheap and widely available chemical could make radiotherapy much more effective at shrinking breast tumors, potentially improving local control and survival.
What could go wrong
This is a phase 2 trial with only 184 participants, so results are preliminary. The approach has been tested mainly in Japan, and side effects like injection-site discomfort may limit acceptance. It is not a cure and is only for specific breast cancer cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 184 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient age 18 years and over * Primary locally advanced breast cancer, or locally recurrent breast cancer with/without metastases (metastases, if present, should be stable or oligometastatic) * Radical/high dose palliative radiotherapy required for lifetime control of local morbidities * Patient physically and mentally fit for radical/high dose palliative radiotherapy * Target tumour accessible for intra-tumoural injection * Patient suitable/compliant with MR protocol * At least one tumour diameter ≥30 mm and ≤150 mm measurable by ultrasound or MR imaging * Patients with predicted life expectancy of 12 months or more * Negative pregnancy test before start of radiotherapy in women of child bearing potential and an ability/willingness to protect against pregnancy from consent and for 3 months post-radiotherapy * Patient offers written informed consent Exclusion Criteria: * Prior radiotherapy to the target area * Maximum diameter of target tumour \<30 mm or \>150mm measurable by ultrasound or MR * Anatomical location and/or extent of disease difficult to access for safe intra-tumoural drug injections, for example by virtue of contiguous major blood vessels and/or brachial plexus * Concomitant chemotherapy or biological therapy except Herceptin, Pertuzumab and Denosumab (all endocrine therapies and bisphosphonates are allowed concomitantly; other cytotoxics and biological therapies apart from those mentioned above should be stopped 3 weeks prior to RT) * Pregnancy or nursing * Hypersensitivity to any of the KORTUC ingredients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Beatson West of Scotland Cancer Centre

    Glasgow, Scotland, G12 0YN, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, CB2 0QQ, United Kingdom

  • Christian Medical Centre

    Vellore, Tamil Nadu, 632004, India

  • Regional Cancer Centre (RCC)

    Trivandrum, Kerala, 695011, India

  • Royal Cornwall Hospitals NHS Trust

    Truro, Cornwall, TR1 3LJ, United Kingdom

  • Tata Medical Centre

    Kolkata, West Bengal, 700160, India

  • Tata Memorial Centre

    Mumbai, India

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, SM2 5PT, United Kingdom

  • University Hospitals of North Midlands NHS Trust

    Stoke-on-Trent, ST4 6QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.